INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Grant or awardVerified data

Renninger Robert reported ATHA

Chief Financial Officer · LeonaBio, Inc. · Athira Pharma, Inc.

Side
A
Value
$2,310
Shares
1,000
Price
$2.31
Executed
Nov 18, 2025
Disclosed
Jan 5, 2026
Disclosure timeline48 days from execution to publication · legal deadline 2 business days
Nov 18 executedJan 5, 2026 disclosed

ATHA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
28/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+5 / 25

$2K reported value · 9.2% of prior position

  • Filing timing+15 / 15

    Disclosed 34 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ATHA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    53
    PJ
    Portman David J.10% Owner
    LONALeonaBio, Inc.
    Open-market purchase
    		BUY$17.33B
    5.50M sh
    		Oct 26, 2026Oct 28, 2026
    traded Oct 26, 2026
    		+2dSEC FORM 4

    Evidence

    53
    PJ
    Portman David J.10% Owner
    LONALeonaBio, Inc.
    Open-market purchase
    		BUY$9.92B
    3.15M sh
    		Oct 26, 2026Oct 28, 2026
    traded Oct 26, 2026
    		+2dSEC FORM 4

    Evidence

    9
    RA
    Romano Kelly ADirector
    LONALeonaBio, Inc.
    Grant or award
    		A—
    28.0K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KB
    Kosacz BarbaraDirector
    LONALeonaBio, Inc.
    Grant or award
    		A—
    28.0K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SB
    Silverman Peter B.Director
    LONALeonaBio, Inc.
    Grant or award
    		A—
    2,333 sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CF
    Callori FredDirector
    LONALeonaBio, Inc.
    Grant or award
    		A—
    2,333 sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SB
    Silverman Peter B.Director
    LONALeonaBio, Inc.
    Grant or award
    		A—
    56.0K sh
    		May 5, 2026May 7, 2026
    traded May 5, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CF
    Callori FredDirector
    LONALeonaBio, Inc.
    Grant or award
    		A—
    56.0K sh
    		May 5, 2026May 7, 2026
    traded May 5, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LJ
    Litton Mark JamesDirector, PRESIDENT and CEO
    LONALeonaBio, Inc.
    Grant or award
    		A—
    750.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    5
    RR
    Renninger RobertCHIEF FINANCIAL OFFICER
    LONALeonaBio, Inc.
    Grant or award
    		A—
    300.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    CK
    Church KevinCHIEF SCIENTIFIC OFFICER
    LONALeonaBio, Inc.
    Grant or award
    		A—
    300.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    KB
    Kosacz BarbaraDirector
    LONALeonaBio, Inc.
    Grant or award
    		A—
    28.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    RA
    Romano Kelly ADirector
    LONALeonaBio, Inc.
    Grant or award
    		A—
    28.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    PA
    Panzara Michael A.Director
    LONALeonaBio, Inc.
    Grant or award
    		A—
    28.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    WM
    Worthington MarkGENERAL COUNSEL and CCO
    LONALeonaBio, Inc.
    Grant or award
    		A—
    300.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SJ
    San Martin JavierCHIEF MEDICAL OFFICER
    LONALeonaBio, Inc.
    Grant or award
    		A—
    350.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    31
    RR
    Renninger RobertCHIEF FINANCIAL OFFICER
    LONALeonaBio, Inc.
    Open-market sale
    		SELL$4,865
    906 sh
    		Mar 4, 2026Mar 5, 2026
    traded Mar 4, 2026
    		+1dSEC FORM 4

    Evidence

    5
    RR
    Renninger RobertCHIEF FINANCIAL OFFICER
    LONALeonaBio, Inc.
    Option exercise
    		M—
    3,900 sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RR
    Renninger RobertCHIEF FINANCIAL OFFICER
    LONALeonaBio, Inc.
    Option exercise
    		M—
    3,900 sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    15
    RR
    Renninger RobertChief Financial Officer
    ATHALeonaBio, Inc.
    Option exercise
    		M—
    1,236 sh
    		Dec 31, 2025Jan 5, 2026
    traded Dec 31, 2025
    		+5dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002037968-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 18, 2025
    Published
    Jan 5, 2026
    Ingested by INSIDER
    Nov 5, 04:24 UTC
    Last re-read
    Nov 5, 04:24 UTC

    Extracted facts

    Filer
    Renninger Robert
    Role
    Chief Financial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Athira Pharma, Inc.
    Ticker
    ATHA
    Shares
    1,000
    Price per share
    $2.31
    Value
    $2,310
    Execution date (reported)
    Nov 18, 2025
    Owned after transaction
    11.9K shares
    Days from execution to publication
    48

    Calculation

    Value = shares × reported price per share

    • Shares: 1,000
    • Price: $2.31

    = $2,310

    What this establishes

    Renninger Robert filed this Form 4 reporting a grant or award of ATHA on Nov 18, 2025. It became public on Jan 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Renninger Robertcik:0002037968
    Issuer
    LeonaBio, Inc.cik:0001620463

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    • Other material event8-KSep 22, 2026
    • Other material event8-KAug 26, 2026
    • Quarterly report (10-Q)10-QAug 14, 2026
    • Results of operations (earnings)8-KAug 14, 2026
    • Quarterly report (10-Q)10-QMay 7, 2026
    • Results of operations (earnings)8-KMay 7, 2026
    • Annual report (10-K)10-KMar 31, 2026
    • Results of operations (earnings)8-KMar 26, 2026
    • Officer or director change · Other material event8-KMar 19, 2026
    • Officer or director change · Other material event8-KJan 9, 2026
    • Entry into a material agreement · Other material event8-KDec 18, 2025
    • Quarterly report (10-Q)10-QNov 6, 2025
    • Results of operations (earnings)8-KNov 6, 2025
    • Other material event8-KOct 3, 2025
    Source error

    Price history for ATHA is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.